BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Parsabiv (Etelcalcetide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Parsabiv (Etelcalcetide)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03969329-878@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Parsabiv (Etelcalcetide): Phase 3 readout est. (NCT03969329)
DESCRIPTION:Parsabiv (Etelcalcetide)\, phase 3\, Secondary Hyperparathyroid
 ism.\nStudy: A Phase 3 Study of Etelcalcetide in Children With Secondary H
 yperparathyroidism Receiving Hemodialysis\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etelcalc
 etide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03969329
URL:https://assetmemo.bio/drug/etelcalcetide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03633708-878@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Parsabiv (Etelcalcetide): Phase 3 readout est. (NCT03633708)
DESCRIPTION:Parsabiv (Etelcalcetide)\, phase 3\, Chronic Kidney Disease.\nS
 tudy: A Trial of Etelcalcetide in Pediatric Participants With Secondary Hy
 perparathyroidism and Chronic Kidney Disease on Hemodialysis\nEstimated pr
 imary completion: 31 January 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/etelcalcetide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03633708
URL:https://assetmemo.bio/drug/etelcalcetide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
